Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$248.00
-0.8%
$225.42
$184.63
$261.64
$438.31B0.38.94 million shs5.78 million shs
Duke Energy Corporation stock logo
DUK
Duke Energy
$125.47
+0.2%
$124.95
$113.89
$134.49
$97.82B0.383.71 million shs2.80 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-4.94%+10.20%+19.11%+30.02%
Duke Energy Corporation stock logo
DUK
Duke Energy
0.00%-3.07%+1.00%-4.88%+6.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$248.00
-0.8%
$225.42
$184.63
$261.64
$438.31B0.38.94 million shs5.78 million shs
Duke Energy Corporation stock logo
DUK
Duke Energy
$125.47
+0.2%
$124.95
$113.89
$134.49
$97.82B0.383.71 million shs2.80 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-4.94%+10.20%+19.11%+30.02%
Duke Energy Corporation stock logo
DUK
Duke Energy
0.00%-3.07%+1.00%-4.88%+6.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.84
Moderate Buy$262.815.97% Upside
Duke Energy Corporation stock logo
DUK
Duke Energy
2.53
Moderate Buy$138.3310.25% Upside

Current Analyst Ratings Breakdown

Latest ABBV and DUK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$260.00 ➝ $295.00
7/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetBuy$234.00 ➝ $276.00
7/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOutperform$260.00 ➝ $280.00
7/9/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetBuy$249.00 ➝ $261.00
7/9/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$260.00 ➝ $280.00
7/6/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingBuy$300.00
7/6/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$240.00 ➝ $265.00
6/24/2026
Duke Energy Corporation stock logo
DUK
Duke Energy
Boost Price Target$132.00 ➝ $136.00
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingMarket Perform
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingOverweight
6/23/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetBuy$265.00 ➝ $273.00
(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$62.82B6.98$15.14 per share16.38($1.83) per share-135.52
Duke Energy Corporation stock logo
DUK
Duke Energy
$32.24B3.03$16.29 per share7.70$66.93 per share1.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$2.03122.1715.460.815.79%-576.45%13.39%7/31/2026 (Estimated)
Duke Energy Corporation stock logo
DUK
Duke Energy
$4.97B$6.5319.2117.57N/A15.49%9.73%2.64%8/4/2026 (Estimated)

Latest ABBV and DUK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Duke Energy Corporation stock logo
DUK
Duke Energy
$1.30N/AN/AN/A$7.62 billionN/A
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.71N/AN/AN/A$16.77 billionN/A
5/4/2026Q1 2026
Duke Energy Corporation stock logo
DUK
Duke Energy
$1.87$1.93+$0.06$1.97$8.44 billion$9.18 billion
4/29/2026Q1 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.79%+6.80%340.89%53 Years
Duke Energy Corporation stock logo
DUK
Duke Energy
$4.263.40%+2.01%65.24%20 Years

Latest ABBV and DUK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.733.19%7/15/20267/15/20268/14/2026
5/7/2026
Duke Energy Corporation stock logo
DUK
Duke Energy
quarterly$1.06503.52%5/15/20265/15/20266/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.80
0.68
Duke Energy Corporation stock logo
DUK
Duke Energy
1.45
0.66
0.44

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Duke Energy Corporation stock logo
DUK
Duke Energy
65.31%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Duke Energy Corporation stock logo
DUK
Duke Energy
0.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Duke Energy Corporation stock logo
DUK
Duke Energy
26,441779.60 million778.66 millionOptionable

Recent News About These Companies

Invest in These 3 Sales Growth Stocks for Robust Returns
Has Duke Energy (DUK) Outpaced Other Utilities Stocks This Year?
Duke makes available $350K in financial assistance

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$248.00 -1.91 (-0.76%)
Closing price 07/10/2026 03:59 PM Eastern
Extended Trading
$248.82 +0.82 (+0.33%)
As of 07/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Duke Energy stock logo

Duke Energy NYSE:DUK

$125.47 +0.21 (+0.17%)
Closing price 07/10/2026 03:59 PM Eastern
Extended Trading
$125.32 -0.14 (-0.11%)
As of 07/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Duke Energy Corporation, together with its subsidiaries, operates as an energy company in the United States. It operates through two segments: Electric Utilities and Infrastructure (EU&I), and Gas Utilities and Infrastructure (GU&I). The EU&I segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, and the Midwest. It generates electricity through coal, hydroelectric, natural gas, oil, solar and wind sources, renewables, and nuclear fuel. This segment also engages in the wholesale of electricity to municipalities, electric cooperative utilities, and load-serving entities. The GU&I segment distributes natural gas to residential, commercial, industrial, and power generation natural gas customers; and invests in pipeline transmission projects, renewable natural gas projects, and natural gas storage facilities. The company was formerly known as Duke Energy Holding Corp. and changed its name to Duke Energy Corporation in April 2006. Duke Energy Corporation was founded in 1904 and is headquartered in Charlotte, North Carolina.